Tagged with EG

France France’s territorial landscape is undergoing a profound shift, and departments are emerging as decisive actors in the response to medical deserts, demographic ageing and the widening gaps in prevention and mental health. In this interview, Philippe Gouet provides a rare, ground-level view of how local authorities are reshaping access to…

France Alexion France is entering a pivotal phase as the rare-disease landscape becomes more competitive, more data driven and increasingly shaped by early access and clinical-trial performance. In this interview, Celine Khalife reflects on France’s shifting position, the evolution of complement and science, the integration of Amolyt Pharma and the growing…

France Biocodex has evolved from a pioneering French laboratory built around a single yeast strain into an international healthcare group spanning microbiota, women’s health and a focused orphan-disease activity. In this conversation, CEO Nicolas Coudurier reflects on the company’s scientific roots, its expansion across more than one hundred markets, and the…

France Nicolas Dufourt leads ALK France as General Manager, drawing on nearly two decades of tenure with the Danish allergy immunotherapy specialist. Under his stewardship, the French affiliate, comprising approximately 400 employees, has emerged as the company’s second-largest market globally. His leadership navigates the complex intersection of increasing allergy prevalence, diminishing…

Taiwan Vincent Tong, Managing Director of MSD Taiwan, brings two decades of pharmaceutical expertise to his second tenure leading the organisation in Taiwan. Having first served in Taiwan in 2008, Tong has witnessed the market’s evolution from emerging economy to sophisticated healthcare innovator. His career spans multiple markets across Asia-Pacific and…

LatAm Alexandre Gibim, senior Vice President of Latin America at AstraZeneca, brings extensive global pharmaceutical leadership experience spanning China, the US, and Canada. In this exclusive interview, he articulates AstraZeneca’s strategic commitment to Latin America as a critical growth engine, detailing the company’s 110 million USD (two billion Mexican peso) investment…

China Founded in 2016, Mabgeek Biotech has quickly emerged as a promising innovator in immunology, pioneering long-acting antibody therapies for allergic and autoimmune diseases, particularly Th2-driven conditions such as atopic dermatitis and asthma. In this interview, Founder and CEO Dr Chenghai Zhang shares how a lean, discovery-driven model and a focus…

France With France at the forefront of rare disease expertise yet increasingly challenged on patient access, Amicus Therapeutics finds itself at the heart of both progress and paradox. In this interview, Caroline Yau, General Manager for France & Benelux, discusses her transition from Big Pharma to biotech, the realities of operating…

France With over two decades of international experience in the pharmaceutical industry, Olivier Zambelli brings both strategic vision and a deeply human approach to his role as President and General Manager of Astellas France. Joining at a time of profound transformation for the organisation, he is leading the affiliate through a…

Brazil After international tenures in Korea and at Servier’s global headquarters in Paris, Matthieu Mendil has taken the helm of Servier Brazil at a pivotal moment in the affiliate’s evolution. Drawing on a global perspective shaped by strategy and operational leadership, he is guiding Servier Brazil to balance its strong cardiometabolic…

Pharma Legal Handbook 1. What are the regulatory authorities with jurisdiction over drugs, biologicals, and medical devices in your country? The Authority that regulates drugs, biologicals and medical devices in Panama is the Ministry of Health through the following authorities:  Pharmaceutical and Drug Department   Medical Devices National Department   Bioethical National Committee.…

Pharma Legal Handbook Preclinical & Clinical Trials in Panama are regulated by Law 78 November 20, 2003; Law 84 of May 14, 2019; Executive Decree 1110 June 6, 2012; Resolution No. 512 of June 28, 2019; Executive Decree 1843 December 16, 2014.   1. Are clinical trials required to be conducted locally as…